For years, treating ADHD meant a familiar cycle: stimulants, side effects, and a lot of guesswork. But the field is changing fast. Right now, researchers are looking beyond traditional medications to understand the biology of ADHD in new ways.
Imagine treating ADHD by gently stimulating specific parts of the brain with a magnetic field. It sounds like science fiction, but Transcranial Magnetic Stimulation (TMS) is becoming a reality. A systematic review published in the Brain and Behaviour reviewed 8 studies and found promising results. The data showed that repetitive TMS (rTMS) is effective at easing symptoms of ADHD particularly inattention [1].
"These findings suggest that non-invasive brain stimulation can modulate the neural circuits underlying ADHD symptoms", the researchers note. "However, optimal stimulation protocols and long-term effects still require further investigation". [1]
Cognitive training has also evolved beyond early "brain game" skepticism. A recent study has revealed that cognitive training is more effective if it is focused on multiple domains and is individually tailored [2]. The field is now shifting toward personalized protocols tailored to an individual’s specific cognitive profile rather than one-size-fits-all programs. At Propel, we have adopted the same approach.
We’ve heard about the Mediterranean diet for heart health, but what about the "MIND" diet for focus? The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet combines the Mediterranean diet with the DASH diet to fight inflammation.
A recent study involving 360 children found that those with the highest adherence to the MIND diet had lower odds of having ADHD [3]. While diet isn't a cure, this suggests that reducing inflammation and boosting antioxidants through food can significantly impact brain function and focus.
Developing new ADHD drugs takes decades. But what if some existing medications for other conditions are effective?
Scientists are doing just that. A groundbreaking study published in Neuropsychopharmacology in 2025 found that amlodipine, a common blood pressure medication, significantly reduced hyperactivity symptoms in animal models [4].
Because this drug is already approved by the FDA, it could be repurposed for ADHD much faster than a new compound, potentially offering a new option with fewer side effects than traditional stimulants.
The trial and error method of finding the right ADHD medication may soon be over. The future of treatment lies in pharmacogenomics.
Researchers are moving toward "polygenic treatment scores". Instead of looking at just one gene, they will analyze thousands of genetic variants to predict which medication you will respond to best [5], and which ones might cause side effects before you even take the first pill. We are entering the era of truly personalized ADHD care.
ADHD research is no longer just about managing symptoms. It's about understanding the individual biology of the brain and using that knowledge to unlock targeted treatments. Whether it is cognitive training, a dietary change, or a gene-guided prescription, the future of ADHD treatment is more personalized and more hopeful than ever.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Please consult with a qualified healthcare professional for diagnosis and treatment options.
Whether you're here to focus better, calm your mind, or just feel a little more in control, we’re here to support you. One game at a time.
